Plain-English translation of NCT07486843 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a newer biologic medication called adalimumab biosimilar is better than methotrexate at slowing down or preventing joint damage in early psoriatic arthritis. You would be randomly assigned to receive one of these two treatments for about a year, with regular imaging scans of your hand joints to track any changes.
Psoriatic arthritis can cause permanent joint damage early on, even in people with mild symptoms. Doctors want to find out which treatment works best at protecting your joints during those critical early months after diagnosis.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic at baseline, at 24 weeks, and at one year. At each visit, you would receive your assigned medication and have a special high-resolution scan of your hand joints to measure any changes in bone structure. You would take either methotrexate by injection or the adalimumab biosimilar injection at home, depending on which group you are randomly assigned to.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Hong Kong